Accellacare US Inc. — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$370,673	81
2024	Research	$641,681	43
2023	Research	$1,481,862	95
2022	Research	$3,751,744	91
2021	Research	$510,381	9

Breakdown

Who paid Research payments · program years 2021–2025

Janssen Pharmaceuticals, Inc $5,438,749 157 payments
Janssen Research & Development, LLC $1,132,934 107 payments
NuVasive, Inc. $102,669 19 payments
Globus Medical, Inc. $81,989 36 payments

Studies the money was for Research payments · program years 2021–2025

A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older $5,438,749 157 payments
70033093Afl3002 $714,482 27 payments
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation $330,372 19 payments
NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine $105,898 14 payments
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants $48,632 1 payment
A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine $46,695 21 payments
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) $14,159 39 payments
NUVA.ACP0721: A prospective, multicenter study evaluating the safety and performance of the NuVasive?? ACP System for the treatment of patients with pathologic conditions of the cervical spine $10,274 3 payments
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder $8,459 7 payments
Cnto1959psa3004 $7,692 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.